Background: Linezolid (LZD) is the first approved oxazolidinone antibiotic and has shown broad activity against gram-positive bacteria, including VRE and MRSA. Previous studies indicated LZD clearance was higher in pediatric patients than in adult patients. In order to characterize the impact of age-related changes in LZD PK, a population PK model was developed using data from neonates and young infants.
Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Diego, California, September 2002
By M. Vo, B.B. Cirincione, C.M. Rubino, and G. L. Jungbluth